Respiratory Drug Delivery (RDD®) 2026

MSP, A Division of TSI®, is pleased to exhibit at RDD® 2026, a leading international conference bringing together around 600 experts from industry, academia, and regulatory authorities to advance respiratory drug delivery science and innovation.

Optimizing Inhaled Drug Delivery Testing

At RDD® 2026, MSP will showcase solutions for inhaler and nebulizer performance testing, supporting pharmaceutical development from early research through to regulatory applications.

A key highlight is the Next Generation Impactor (NGI) for accurate and reproducible aerodynamic particle size distribution (APSD) measurements.

NGI for SMI & Nebulizer Applications:

• Improve IVIVC using patient-relevant profiles
• Reduce variability by minimizing evaporation effects
• Deliver consistent, regulatory-relevant data for product development

Comprehensive OINDP Expertise

MSP’s Pharmaceuticals Inhaler Device Testing group is a trusted partner in the OINDP industry, offering products, services, and consulting for pharmaceutical development.

In collaboration with Copley Scientific, we provide complete systems for APSD and DDU testing, including advanced automation solutions to improve data reliability and consistency.

Our expertise includes:

• Solutions for generic drug development, including AIM and IVIVC tools
• Strong industry partnerships and deep application knowledge
• Continuous alignment with regulatory standards and best practices

Come to visit us at the booth!

 

---

Connect with Us

Can't wait until the event? Connect with us online to stay updated on the latest news, product releases, and industry insights from MSP, a Division of TSI®. Follow us on LinkedIn for real-time updates and exclusive content.